Literature DB >> 2043940

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

B G Weinshenker1, G P Rice, J H Noseworthy, W Carriere, J Baskerville, G C Ebers.   

Abstract

A multivariate hierarchical analysis was used to assess the significance of several demographic and clinical factors in multiple sclerosis patients. We used the time to reach level 6 on the disability status scale (DSS) of Kurtzke as endpoint. Several factors at presentation were significantly associated with an adverse outcome including older age at onset, male sex, cerebellar involvement or insidious onset of a motor deficit as first symptom. Factors ascertained later which were associated significantly with a worse outcome, even after controlling for those previously mentioned, included persisting deficits in brainstem, cerebellar or cerebral systems, a higher frequency of attacks in the first 2 yrs after onset of disease, a short first interattack interval and higher DSS at 2 yrs and 5 yrs from onset. An analysis similar to multiple regression was used to generate predictive models which permit the calculation of the median time to DSS 6 for patients with a given set of covariates. The goodness of fit of these models to the data and their predictive accuracy are discussed.

Entities:  

Mesh:

Year:  1991        PMID: 2043940     DOI: 10.1093/brain/114.2.1045

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  69 in total

1.  Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.

Authors:  D Parkin; A Jacoby; P McNamee; P Miller; S Thomas; D Bates
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

2.  Natural history of multiple sclerosis.

Authors:  G C Ebers
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

3.  Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.

Authors:  Cathie L M Sudlow; Carl E Counsell
Journal:  BMJ       Date:  2003-02-15

Review 4.  Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errors.

Authors:  Douglas S Goodin
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 5.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 6.  Prognostic factors for multiple sclerosis: the importance of natural history studies.

Authors:  George C Ebers
Journal:  J Neurol       Date:  2005-09       Impact factor: 4.849

7.  CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS.

Authors:  A Martínez-Yélamos; A Rovira; R Sánchez-Valle; S Martínez-Yélamos; M Tintoré; Y Blanco; F Graus; X Montalban; T Arbizu; A Saiz
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

8.  European validation of a standardized clinical description of multiple sclerosis.

Authors:  Maria Pia Amato; Jerome Grimaud; Iuliana Achiti; Maria Letizia Bartolozzi; Patrice Adeleine; Hans-Peter Hartung; Ludwig Kappos; Alan Thompson; Maria Trojano; Sandra Vukusic; Christian Confavreux
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

9.  Prevalence of Multiple Sclerosis in the Middle Black Sea Region of Turkey and Demographic Characteristics of Patients.

Authors:  Neslihan Akdemir; Murat Terzi; Nilden Arslan; Musa Onar
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

10.  The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?

Authors:  Eric C Klawiter; Anne H Cross; Robert T Naismith
Journal:  Neurology       Date:  2009-09-22       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.